Affiliation:
1. Department of Statistics and Probability, Michigan State University , East Lansing, MI 48824 , USA
2. Department of Computational Mathematics, Science and Engineering, Michigan State University , East Lansing, MI 48824 , USA
Abstract
Abstract
Genome-wide Association Studies (GWAS) methods have identified individual single-nucleotide polymorphisms (SNPs) significantly associated with specific phenotypes. Nonetheless, many complex diseases are polygenic and are controlled by multiple genetic variants that are usually non-linearly dependent. These genetic variants are marginally less effective and remain undetected in GWAS analysis. Kernel-based tests (KBT), which evaluate the joint effect of a group of genetic variants, are therefore critical for complex disease analysis. However, choosing different kernel functions in KBT can significantly influence the type I error control and power, and selecting the optimal kernel remains a statistically challenging task. A few existing methods suffer from inflated type 1 errors, limited scalability, inferior power or issues of ambiguous conclusions. Here, we present a new Bayesian framework, BayesKAT (https://github.com/wangjr03/BayesKAT), which overcomes these kernel specification issues by selecting the optimal composite kernel adaptively from the data while testing genetic associations simultaneously. Furthermore, BayesKAT implements a scalable computational strategy to boost its applicability, especially for high-dimensional cases where other methods become less effective. Based on a series of performance comparisons using both simulated and real large-scale genetics data, BayesKAT outperforms the available methods in detecting complex group-level associations and controlling type I errors simultaneously. Applied on a variety of groups of functionally related genetic variants based on biological pathways, co-expression gene modules and protein complexes, BayesKAT deciphers the complex genetic basis and provides mechanistic insights into human diseases.
Funder
National Institutes of Health
National Science Foundation
Alzheimer's Disease Neuroimaging Initiative
Department of Defense
National Institute on Aging
National Institute of Biomedical Imaging and Bioengineering
Alzheimer's Association
Alzheimer's Drug Discovery Foundation
Araclon Biotech
BioClinica, Inc.
Biogen
Bristol-Myers Squibb Company
CereSpir, Inc.
Cogstate
Eisai Inc.
Elan Pharmaceuticals, Inc.
Eli Lilly and Company
EuroImmun
F. Hoffmann-La Roche Ltd
Genentech, Inc.
Fujirebio
GE Healthcare
IXICO Ltd
Janssen Alzheimer Immunotherapy Research & Development
Johnson & Johnson Pharmaceutical Research & Development LLC.
Lumosity
Lundbeck
Merck & Co., Inc.
Meso Scale Diagnostics
NeuroRx Research
Neurotrack Technologies
Novartis Pharmaceuticals Corporation
Pfizer Inc.
Piramal Imaging
Servier
Takeda Pharmaceutical Company
Transition Therapeutics
Publisher
Oxford University Press (OUP)